CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 98 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2018. The put-call ratio across all filers is 0.96 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $2,558,000 | +354.4% | 196,846 | -53.2% | 0.54% | +176.8% |
| Q1 2020 | $563,000 | -20.5% | 420,846 | 0.0% | 0.19% | -4.0% |
| Q4 2019 | $708,000 | -21.0% | 420,846 | 0.0% | 0.20% | -7.3% |
| Q3 2019 | $896,000 | -20.5% | 420,846 | 0.0% | 0.22% | -4.0% |
| Q2 2019 | $1,127,000 | -45.6% | 420,846 | 0.0% | 0.23% | -41.5% |
| Q1 2019 | $2,071,000 | +65.8% | 420,846 | -93.3% | 0.39% | +51.0% |
| Q4 2018 | $1,249,000 | -56.1% | 6,312,700 | 0.0% | 0.26% | -58.0% |
| Q3 2018 | $2,847,000 | -10.4% | 6,312,700 | 0.0% | 0.61% | -1.4% |
| Q2 2018 | $3,179,000 | -78.4% | 6,312,700 | 0.0% | 0.62% | -73.2% |
| Q1 2018 | $14,708,000 | -18.0% | 6,312,700 | 0.0% | 2.31% | +0.2% |
| Q4 2017 | $17,928,000 | -0.7% | 6,312,700 | 0.0% | 2.31% | -15.8% |
| Q3 2017 | $18,054,000 | +26.0% | 6,312,700 | +8.8% | 2.74% | +27.1% |
| Q2 2017 | $14,326,000 | -4.3% | 5,800,000 | +39.9% | 2.16% | -19.4% |
| Q1 2017 | $14,966,000 | – | 4,145,900 | – | 2.68% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| KLP Enterprises, LLC | 6,865,006 | $16,957,000 | 100.00% |
| Meditor Group Ltd | 5,800,000 | $14,326,000 | 2.16% |
| TSP Capital Management Group, LLC | 1,135,748 | $2,805,000 | 1.29% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 8,526,619 | $21,061,000 | 0.30% |
| Marcus Capital, LLC | 103,800 | $256,000 | 0.22% |
| Benchmark Capital Advisors | 64,800 | $160,000 | 0.13% |
| Vident Investment Advisory, LLC | 480,018 | $1,186,000 | 0.10% |
| Bellevue Group AG | 160,000 | $395,000 | 0.05% |
| NJ State Employees Deferred Compensation Plan | 100,000 | $247,000 | 0.05% |
| Virtus ETF Advisers LLC | 126,989 | $314,000 | 0.05% |